Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma

Third-line sunitinib is occasionally used for selected patients with metastatic renal cell carcinoma (mRCC). The aim of the present study was to evaluate the clinical significance of third-line sunitinib after failure of first-line cytokine therapy and second-line sorafenib in patients with clear-ce...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Clin Oncol
Asıl Yazarlar: Fujita, Tetsuo, Hirayama, Takahiro, Nishi, Morihiro, Matsumoto, Kazumasa, Yoshida, Kazunari, Iwamura, Masatsugu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2019
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6781811/
https://ncbi.nlm.nih.gov/pubmed/31616562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1924
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller